Beamion LUNG‑1 Trial: Zongertinib in HER2-Positive NSCLC

Joshua K. Sabari, MD, describes the design and outcomes of the Beamion LUNG‑1 trial, which supported the FDA approvals of zongertinib in both treatment-naive and previously treated patients with HER2 mutation–positive non–small cell lung cancer. Along with dosing details, he highlights efficacy and safety outcomes across several patient cohorts in the trial.